
Repligen Corporation RGEN
$ 132.12
1.53%
Quarterly report 2026-Q1
added 05-06-2026
Repligen Corporation Accounts Receivables 2011-2026 | RGEN
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Repligen Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 159 M | 134 M | 124 M | 116 M | 117 M | 71.3 M | 43.1 M | 33 M | 27.6 M | 15.2 M | 11.3 M | 7.76 M | 4.95 M | 4.16 M | 2.83 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 159 M | 2.83 M | 58.1 M |
Quarterly Accounts Receivables Repligen Corporation
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 152 M | 149 M | 157 M | 147 M | 134 M | 129 M | 123 M | 116 M | 124 M | 106 M | 120 M | 133 M | 116 M | 118 M | - | 122 M | 117 M | 122 M | 103 M | 90.2 M | 71.4 M | 71.4 M | 71.4 M | 71.4 M | 43.1 M | 43.1 M | 43.1 M | 43.1 M | 33 M | 33 M | 33 M | 33 M | 27.6 M | 27.6 M | 27.6 M | 27.6 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | 7.76 M | 7.76 M | 7.76 M | 7.76 M | 4.95 M | 4.95 M | 4.95 M | 4.95 M | 4.16 M | 4.16 M | 4.16 M | 4.16 M | 2.83 M | 2.83 M | 2.83 M | 2.83 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 157 M | 2.83 M | 55.3 M |
Accounts Receivables of other stocks in the Medical instruments industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
23 K | - | - | $ 810 M | ||
|
The Cooper Companies
COO
|
829 M | $ 68.25 | -0.55 % | $ 13.6 B | ||
|
Glaukos Corporation
GKOS
|
109 M | $ 122.55 | -3.07 % | $ 7.01 B | ||
|
Intuitive Surgical
ISRG
|
1.53 B | $ 419.96 | -1.56 % | $ 150 B | ||
|
ICU Medical
ICUI
|
181 M | $ 142.71 | 0.5 % | $ 3.52 B | ||
|
Repro Med Systems
KRMD
|
6.21 M | $ 3.99 | -0.38 % | $ 184 M | ||
|
iRhythm Technologies
IRTC
|
75.7 M | $ 114.58 | 0.65 % | $ 3.67 B | ||
|
LeMaitre Vascular
LMAT
|
33.6 M | $ 95.89 | -0.72 % | $ 2.17 B | ||
|
Masimo Corporation
MASI
|
141 M | $ 179.95 | - | $ 9.59 B | ||
|
Microbot Medical
MBOT
|
159 K | $ 1.8 | -1.1 % | $ 82.4 M | ||
|
Ekso Bionics Holdings
EKSO
|
7.31 M | - | - | $ 28.6 M | ||
|
Milestone Scientific
MLSS
|
475 K | $ 0.39 | 1.94 % | $ 32 M | ||
|
Merit Medical Systems
MMSI
|
204 M | $ 67.28 | -0.35 % | $ 3.98 B | ||
|
electroCore
ECOR
|
1.03 M | $ 9.55 | 0.32 % | $ 81 K | ||
|
Envista Holdings Corporation
NVST
|
430 M | $ 24.55 | -0.16 % | $ 4.12 B | ||
|
Haemonetics Corporation
HAE
|
217 M | $ 79.52 | 0.99 % | $ 3.75 B | ||
|
STERIS plc
STE
|
1.09 B | $ 211.01 | -0.88 % | $ 20.7 B | ||
|
Isoray
ISR
|
6 K | - | 0.03 % | $ 108 M | ||
|
STAAR Surgical Company
STAA
|
50.1 M | $ 29.77 | -0.35 % | $ 1.48 B | ||
|
InfuSystem Holdings
INFU
|
22.9 M | $ 8.96 | -0.55 % | $ 185 M | ||
|
Teleflex Incorporated
TFX
|
346 M | $ 135.61 | -0.1 % | $ 6.05 B | ||
|
Utah Medical Products
UTMD
|
3.52 M | $ 68.56 | 0.72 % | $ 222 M | ||
|
West Pharmaceutical Services
WST
|
574 M | $ 330.06 | -1.45 % | $ 23.9 B | ||
|
Pulse Biosciences
PLSE
|
274 K | $ 25.13 | -2.5 % | $ 1.69 B | ||
|
Retractable Technologies
RVP
|
7.9 M | $ 0.68 | -1.18 % | $ 20.4 M | ||
|
Pro-Dex
PDEX
|
16.4 M | $ 64.36 | -0.99 % | $ 212 M | ||
|
Predictive Oncology
POAI
|
32.1 K | - | - | $ 31.1 M | ||
|
BioLife Solutions
BLFS
|
7.95 M | $ 27.44 | -0.42 % | $ 1.31 B | ||
|
Stereotaxis
STXS
|
5.85 M | $ 1.86 | 0.27 % | $ 169 M | ||
|
Baxter International
BAX
|
1.7 B | $ 20.68 | 3.25 % | $ 10.6 B | ||
|
ResMed
RMD
|
576 M | $ 196.55 | -0.2 % | $ 28.7 B | ||
|
AtriCure
ATRC
|
66.7 M | $ 27.43 | 0.48 % | $ 1.31 B | ||
|
Harvard Bioscience
HBIO
|
16 M | $ 6.28 | 3.97 % | $ 279 M | ||
|
NeuroMetrix
NURO
|
193 K | - | 5.05 % | $ 9.02 M | ||
|
AngioDynamics
ANGO
|
42.9 M | $ 12.41 | 0.57 % | $ 507 M | ||
|
Becton, Dickinson and Company
BDX
|
2.99 B | $ 150.36 | -1.11 % | $ 43.3 B | ||
|
Nephros
NEPH
|
2.41 M | $ 3.24 | -0.46 % | $ 34.4 M | ||
|
OraSure Technologies
OSUR
|
22.2 M | $ 4.2 | -1.06 % | $ 309 M |